No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
APLT Applied Therapeutics
- 4.760
- +0.230+5.08%
Close May 3 16:00 ET
- 4.702
- -0.058-1.21%
Post 16:42 ET
543.79MMarket Cap-3352P/E (TTM)
4.860High4.605Low622.61KVolume4.630Open4.530Pre Close2.97MTurnover0.66%Turnover RatioLossP/E (Static)114.24MShares9.39052wk High-31.73P/B450.99MFloat Cap1.18052wk Low--Dividend TTM94.75MShs Float57.390Historical High--Div YieldTTM5.63%Amplitude0.500Historical Low4.763Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Applied Therapeutics Welcomes Dale Hooks as New CCO
RBC Capital Sticks to Their Buy Rating for Applied Therapeutics (APLT)
Applied Therapeutics Price Target Maintained With a $12.00/Share by RBC Capital
Applied Therapeutics Price Target Maintained With a $12.00/Share by RBC Capital
RBC Capital Reiterates Outperform on Applied Therapeutics, Maintains $12 Price Target
RBC Capital analyst Brian Abrahams reiterates Applied Therapeutics with a Outperform and maintains $12 price target.
CNDT, CHRS and OM Are Among Materials Movers
Applied Therapeutics Plans To Present Results From Phase 3 ARISE-HF Study In Diabetic Cardiomyopathy At ACC 2024
Applied Therapeutics Plans To Present Results From Phase 3 ARISE-HF Study In Diabetic Cardiomyopathy At ACC 2024
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg